{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T01:17:33Z","timestamp":1760577453178,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Eveards Therapy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s10792-020-01471-9","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T09:25:14Z","timestamp":1593681914000},"page":"2865-2874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of injecting increasing volumes into the extravascular spaces of the choroid using a blunt adjustable depth injector"],"prefix":"10.1007","volume":"40","author":[{"given":"Ifat","family":"Sher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettel","family":"Bubis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadas","family":"Ketter-Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehavit","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawan","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2366-1779","authenticated-orcid":false,"given":"Ygal","family":"Rotenstreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"key":"1471_CR1","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1517\/17425247.2014.935338","volume":"11","author":"JJ Kang-Mieler","year":"2014","unstructured":"Kang-Mieler JJ, Osswald CR, Mieler WF (2014) Advances in ocular drug delivery: emphasis on the posterior segment. Expert Opin Drug Deliv 11:1647\u20131660","journal-title":"Expert Opin Drug Deliv"},{"key":"1471_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1517\/17425247.4.4.371","volume":"4","author":"KG Janoria","year":"2007","unstructured":"Janoria KG, Gunda S, Boddu SH, Mitra AK (2007) Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 4:371\u2013388","journal-title":"Expert Opin Drug Deliv"},{"key":"1471_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/jamaophthalmol.2015.186","volume":"133","author":"SB Bressler","year":"2015","unstructured":"Bressler SB, Almukhtar T, Bhorade A et al (2015) Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 133:589\u2013597. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.186","journal-title":"JAMA Ophthalmol"},{"key":"1471_CR4","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444. https:\/\/doi.org\/10.1056\/NEJMoa062655","journal-title":"N Engl J Med"},{"key":"1471_CR5","doi-asserted-by":"publisher","first-page":"930-4.e1","DOI":"10.1016\/j.ajo.2008.07.007","volume":"146","author":"JE Kim","year":"2008","unstructured":"Kim JE, Mantravadi AV, Hur EY, Covert DJ (2008) Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 146:930-4.e1. https:\/\/doi.org\/10.1016\/j.ajo.2008.07.007","journal-title":"Am J Ophthalmol"},{"key":"1471_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1089\/jop.2009.0076","volume":"26","author":"RA Adelman","year":"2010","unstructured":"Adelman RA, Zheng Q, Mayer HR (2010) Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 26:105\u2013110. https:\/\/doi.org\/10.1089\/jop.2009.0076","journal-title":"J Ocul Pharmacol Ther"},{"key":"1471_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1097\/IAE.0000000000000531","volume":"35","author":"EE Karaca","year":"2015","unstructured":"Karaca EE, Kepez Yldz B, \u00c7ubuk M\u00d6, \u00d6zdek \u015e (2015) Epiretinal membranes in neovascular age-related macular degeneration: effect on outcomes of anti-vascular endothelial growth factor therapy. Retina (Philadelphia, Pa) 35:1540\u20131546. https:\/\/doi.org\/10.1097\/IAE.0000000000000531","journal-title":"Retina (Philadelphia, Pa)"},{"key":"1471_CR8","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1111\/aos.13238","volume":"95","author":"Y Rotenstreich","year":"2017","unstructured":"Rotenstreich Y, Tzameret A, Kalish SE et al (2017) A minimally invasive adjustable-depth blunt injector for delivery of pharmaceuticals into the posterior pole. Acta Ophthalmol 95:e197\u2013e205. https:\/\/doi.org\/10.1111\/aos.13238","journal-title":"Acta Ophthalmol"},{"key":"1471_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.exer.2013.10.023","volume":"118","author":"A Tzameret","year":"2014","unstructured":"Tzameret A, Sher I, Belkin M et al (2014) Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer ameliorates retinal degeneration in a rat model of retinal dystrophy. Exp Eye Res 118:135\u2013144. https:\/\/doi.org\/10.1016\/j.exer.2013.10.023","journal-title":"Exp Eye Res"},{"key":"1471_CR10","doi-asserted-by":"publisher","first-page":"4061975","DOI":"10.1155\/2017\/4061975","volume":"2017","author":"A Tzameret","year":"2017","unstructured":"Tzameret A, Kalish SE, Sher I et al (2017) Long-term safety of transplanting human bone marrow stromal cells into the extravascular spaces of the choroid of rabbits. Stem Cells Int 2017:4061975. https:\/\/doi.org\/10.1155\/2017\/4061975","journal-title":"Stem Cells Int"},{"key":"1471_CR11","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1097\/IAE.0000000000000476","volume":"35","author":"CE Pang","year":"2015","unstructured":"Pang CE, Mrejen S, Hoang QV et al (2015) Association between needle size, postinjection reflux, and intraocular pressure spikes after intravitreal injections. Retina (Philadelphia, Pa) 35:1401\u20131406. https:\/\/doi.org\/10.1097\/IAE.0000000000000476","journal-title":"Retina (Philadelphia, Pa)"},{"key":"1471_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.exer.2016.03.008","volume":"145","author":"B Chiang","year":"2016","unstructured":"Chiang B, Kim YC, Edelhauser HF, Prausnitz MR (2016) Circumferential flow of particles in the suprachoroidal space is impeded by the posterior ciliary arteries. Exp Eye Res 145:424\u2013431. https:\/\/doi.org\/10.1016\/j.exer.2016.03.008","journal-title":"Exp Eye Res"},{"key":"1471_CR13","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1167\/iovs.17-23758","volume":"59","author":"JH Jung","year":"2018","unstructured":"Jung JH, Desit P, Prausnitz MR (2018) Targeted drug delivery in the suprachoroidal space by swollen hydrogel pushing. Invest Ophthalmol Vis Sci 59:2069\u20132079. https:\/\/doi.org\/10.1167\/iovs.17-23758","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1471_CR14","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1167\/iovs.15-16597","volume":"56","author":"B Gu","year":"2015","unstructured":"Gu B, Liu J, Li X et al (2015) Real-time monitoring of suprachoroidal space (SCS) following SCS injection using ultra-high resolution optical coherence tomography in guinea pig eyes. Invest Ophthalmol Vis Sci 56:3623\u20133634. https:\/\/doi.org\/10.1167\/iovs.15-16597","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1471_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0140-6736(12)60028-2","volume":"379","author":"SD Schwartz","year":"2012","unstructured":"Schwartz SD, Hubschman J-P, Heilwell G et al (2012) Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379:713\u2013720. https:\/\/doi.org\/10.1016\/S0140-6736(12)60028-2","journal-title":"Lancet"},{"key":"1471_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/mt.2012.280","volume":"21","author":"SE Boye","year":"2013","unstructured":"Boye SE, Boye SL, Lewin AS, Hauswirth WW (2013) A comprehensive review of retinal gene therapy. Mol Ther 21:509\u2013519. https:\/\/doi.org\/10.1038\/mt.2012.280","journal-title":"Mol Ther"},{"key":"1471_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0140-6736(14)61376-3","volume":"385","author":"SD Schwartz","year":"2015","unstructured":"Schwartz SD, Regillo CD, Lam BL et al (2015) Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt\u2019s macular dystrophy: follow-up of two open-label phase 1\/2 studies. Lancet 385:509\u2013516. https:\/\/doi.org\/10.1016\/S0140-6736(14)61376-3","journal-title":"Lancet"},{"key":"1471_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11095-018-2554-7","volume":"36","author":"GA Rodrigues","year":"2018","unstructured":"Rodrigues GA, Shalaev E, Karami TK et al (2018) Pharmaceutical development of AAV-based gene therapy products for the eye. Pharm Res 36:29. https:\/\/doi.org\/10.1007\/s11095-018-2554-7","journal-title":"Pharm Res"},{"key":"1471_CR19","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1002\/stem.149","volume":"27","author":"B Lu","year":"2009","unstructured":"Lu B, Malcuit C, Wang S et al (2009) Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells 27:2126\u20132135. https:\/\/doi.org\/10.1002\/stem.149","journal-title":"Stem Cells"},{"key":"1471_CR20","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"Maguire AM, Simonelli F, Pierce EA et al (2008) Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis. N Engl J Med 358:2240\u20132248. https:\/\/doi.org\/10.1056\/NEJMoa0802315","journal-title":"N Engl J Med"},{"key":"1471_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrg2717","volume":"11","author":"AF Wright","year":"2010","unstructured":"Wright AF, Chakarova CF, Abd El-Aziz MM, Bhattacharya SS (2010) Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait. Nat Rev Genet 11:273\u2013284. https:\/\/doi.org\/10.1038\/nrg2717","journal-title":"Nat Rev Genet"},{"key":"1471_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archophthalmol.2011.295","volume":"130","author":"TM Nork","year":"2012","unstructured":"Nork TM, Murphy CJ, Kim CBY et al (2012) Functional and anatomic consequences of subretinal dosing in the cynomolgus macaque. Arch Ophthalmol 130:65\u201375. https:\/\/doi.org\/10.1001\/archophthalmol.2011.295","journal-title":"Arch Ophthalmol"},{"key":"1471_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.omtm.2019.08.011","volume":"15","author":"L Weed","year":"2019","unstructured":"Weed L, Ammar MJ, Zhou S et al (2019) Safety of same-eye subretinal sequential readministration of AAV2-hRPE65v2 in non-human primates. Mol Ther Methods Clin Dev 15:133\u2013148. https:\/\/doi.org\/10.1016\/j.omtm.2019.08.011","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1471_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","volume":"130","author":"SG Jacobson","year":"2012","unstructured":"Jacobson SG, Cideciyan AV, Ratnakaram R et al (2012) Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130:9\u201324. https:\/\/doi.org\/10.1001\/archophthalmol.2011.298","journal-title":"Arch Ophthalmol"},{"key":"1471_CR25","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ophtha.2016.03.003","volume":"123","author":"RG Weleber","year":"2016","unstructured":"Weleber RG, Pennesi ME, Wilson DJ et al (2016) Results at 2 years after gene therapy for RPE65-deficient leber congenital amaurosis and severe early-childhood-onset retinal dystrophy. Ophthalmology 123:1606\u20131620. https:\/\/doi.org\/10.1016\/j.ophtha.2016.03.003","journal-title":"Ophthalmology"},{"key":"1471_CR26","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1089\/hum.2018.014","volume":"29","author":"ME Pennesi","year":"2018","unstructured":"Pennesi ME, Weleber RG, Yang P et al (2018) Results at 5 years after gene therapy for RPE65-deficient retinal dystrophy. Hum Gene Ther 29:1428\u20131437. https:\/\/doi.org\/10.1089\/hum.2018.014","journal-title":"Hum Gene Ther"},{"key":"1471_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3928\/23258160-20191009-01","volume":"50","author":"RM Hussain","year":"2019","unstructured":"Hussain RM, Tran KD, Berrocal AM (2019) Subretinal injection of voretigene neparvovec-rzyl in a patient with RPE65-associated leber\u2019s congenital amaurosis. OSLI 50:661\u2013663","journal-title":"OSLI"},{"key":"1471_CR28","first-page":"855","volume":"37","author":"PF Lopez","year":"1996","unstructured":"Lopez PF, Sippy BD, Lambert HM et al (1996) Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37:855\u2013868","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1471_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S0002-9394(14)70522-7","volume":"122","author":"A Kvanta","year":"1996","unstructured":"Kvanta A, Algvere PV, Berglin L, Seregard S (1996) Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Am J Ophthalmol 122:763. https:\/\/doi.org\/10.1016\/S0002-9394(14)70522-7","journal-title":"Am J Ophthalmol"},{"key":"1471_CR30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","volume":"26","author":"N Ferrara","year":"2006","unstructured":"Ferrara N, Damico L, Shams N et al (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina (Philadelphia, Pa) 26:859\u2013870. https:\/\/doi.org\/10.1097\/01.iae.0000242842.14624.e7","journal-title":"Retina (Philadelphia, Pa)"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01471-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-020-01471-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01471-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T23:20:01Z","timestamp":1625181601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-020-01471-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1471"],"URL":"https:\/\/doi.org\/10.1007\/s10792-020-01471-9","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"type":"print","value":"0165-5701"},{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2020,7,2]]},"assertion":[{"value":"27 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ygal Rotenstreich is an inventor of patents related to the subject matter, a co-founder and a consultant to Everads Therapy. Ifat Sher is a co-founder and a consultant to Everads Therapy. This potential conflict of interest is managed by the Sheba Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional Animal Care Committee at the Sheba Medical Center, Tel-Hashomer, approved and supervised all procedures and experiments. All experiments adhered to the recommendations of the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}